On June 4, 2020, Tetraphase Pharmaceuticals, Inc. received notice that the United States Food and Drug Administration (the FDA) approved the Company's supplemental New Drug application (sNDA) for a new strength of XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections in adult patients containing 100mg of eravacycline per vial as well as an extension of the in-use shelf life for XERAVA diluted ready for infusion IV solution from 7 days to 10 days under refrigerated conditions for the existing 50 mg/vial product and for the newly approved 100 mg/vial product.